​

Funding Round

Post-IPO Equity - Savara Pharmaceuticals

Post-IPO Equity - Savara Pharmaceuticals

Investment Firm

Overview

Savara Pharmaceuticals develops an inhaled antibiotic for MRSA infection in cystic fibrosis.

Announced Date

Jun 28, 2024

Funding Type

Post Ipo Equity

Highlights

Location

United States, North America

Social

Investor Lead

N/A

Participant Investors

7

Investor Name
Participant InvestorFrazier Life Sciences
Participant InvestorBain Capital Life Sciences
Participant InvestorTCG Crossover
Participant InvestorWellington Management
Participant InvestorFarallon Capital Management

Round Details and Background

Savara Pharmaceuticals raised $100000000 on 2024-06-28 in Post-IPO Equity

Savara Pharmaceuticals develops an inhaled antibiotic for MRSA infection in cystic fibrosis.

Company Funding History

15

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Sep 21, 2010
Series A - Savara Pharmaceuticals
-undefined
Mar 01, 2016
Series C - Savara Pharmaceuticals
5-20.0M
Jun 13, 2012
Series B - Savara Pharmaceuticals
3-undefined
Jun 26, 2013
Series B - Savara Pharmaceuticals
-14.3M

Recent Activity

There is no recent news or activity for this profile.